Last reviewed · How we verify
Travatan (TRAVOPROST)
Travatan works by increasing the outflow of fluid from the eye to reduce pressure.
Travatan (TRAVOPROST) is a prostaglandin analog, a small molecule drug that targets the prostaglandin F2-alpha receptor. It was originally developed and is currently owned by Glaukos. Travatan is FDA-approved for the treatment of ocular hypertension and open-angle glaucoma, and has been commercially available since 2001. The drug is now off-patent, with multiple generic manufacturers available. As a prostaglandin analog, Travatan works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure.
At a glance
| Generic name | TRAVOPROST |
|---|---|
| Sponsor | Glaukos |
| Drug class | Prostaglandin Analog [EPC] |
| Target | Prostaglandin F2-alpha receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 2001 |
Mechanism of action
Travoprost free acid, prostaglandin analog is selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.
Approved indications
- Reduction of elevated IOP
Common side effects
- Conjunctival hyperemia
- Ocular hyperemia
- Decreased visual acuity
- Eye discomfort
- Foreign body sensation
- Pain
- Pruritus
- Abnormal vision
- Blepharitis
- Blurred vision
- Cataract
- Conjunctivitis
Key clinical trials
- Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE2,PHASE3)
- Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
- Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone (PHASE4)
- Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone (PHASE3)
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma (PHASE4)
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 9144561 | 2029-03-13 | Formulation |
| 8722735 | 2029-10-10 | Formulation |
| 8754123 | 2029-05-19 | Formulation |
| 8323630 | 2027-09-20 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Travatan CI brief — competitive landscape report
- Travatan updates RSS · CI watch RSS